17 completed, 4 terminated, 2 withdrawn, 1 not yet recruiting. 16 Phase 1, 5 Not applicable, 5 Phase 2, 3 Phase 3.
Follow Stage III Rectal Cancer: new trials by email Literature Review of Stage III Rectal Cancer trials Research Report on Stage III Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quicksilver II Pilot Study Direct-to-surgery (i.e., no neoadjuvant chemotherapy), Control Group - Stage II Rectal Cancer, Stage III Rectal Cancer | Not applicable | Not yet recruiting | Mount Sinai Hospital, Canada | 18 | 2026-09-01 | 2026-07-07 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Bevacizumab, Dasatinib, Fluorouracil - Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Completed | Anne Noonan | 9 | 2020-09-02 | 2024-12-27 |
| The Role of Vitamin D in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer Vitamin D - Rectal Cancer, Stage III Rectal Cancer | Unknown | Istanbul Training and Research Hospital | 60 | 2020-09-01 | 2022-08-08 | |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer questionnaire administration, laboratory biomarker analysis, Standard Dietary Intervention - Stage I Colon Cancer, Stage II Colon Cancer | Not applicable | Completed | Case Comprehensive Cancer Center | 18 | 2015-02-16 | 2018-07-20 |
| Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry - Recurrent Colon Cancer, Recurrent Gastric Cancer | Phase 1 | Completed | City of Hope Medical Center | 12 | 2011-12-22 | 2026-10-19 |
| Laparoscopic Surgery or Robotic-Assisted Laparoscopic Surgery in Treating Patients With Rectal Cancer That Can Be Removed By Surgery conventional laparoscopic surgery, robotic-assisted laparoscopic surgery, quality-of-life assessment - Recurrent Rectal Cancer, Stage I Rectal Cancer | Not applicable | Withdrawn | City of Hope Medical Center | 2011-12-01 | 2012-04-17 | |
| Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma Capecitabine, 5-FU, Leucovorin - Stage II Rectal Cancer, Stage III Rectal Cancer | Phase 1 / Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2011-03-01 | 2020-08-20 | |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-10-01 | 2015-03-31 |
| Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery resveratrol, pharmacological study, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2006-12-01 | 2014-09-15 |
| Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer oxaliplatin, fluorouracil, leucovorin calcium - Adenocarcinoma of the Rectum, Stage II Rectal Cancer | Phase 3 | Terminated | ECOG-ACRIN Cancer Research Group | 355 | 2006-05-11 | 2023-07-06 |
| Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors oxaliplatin, leucovorin calcium, vorinostat - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2005-07-01 | 2013-09-30 |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer sorafenib tosylate, cetuximab, irinotecan hydrochloride - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 48 | 2005-06-01 | 2014-04-16 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer EF5, motexafin lutetium, pharmacological study - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Not applicable | Terminated | National Cancer Institute (NCI) | 30 | 2004-05-01 | 2013-01-16 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer oxaliplatin, leucovorin calcium, capecitabine - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 3 | Terminated | National Cancer Institute (NCI) | 2200 | 2004-04-01 | 2013-01-25 |
| Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer bevacizumab, fluorouracil, external beam radiation therapy - Adenocarcinoma of the Rectum, Stage II Rectal Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 32 | 2002-08-01 | 2013-06-05 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant - Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder | Phase 1 | Completed | National Cancer Institute (NCI) | 48 | 2001-11-01 | 2013-01-25 |
Showing 20 of 25. Sign in to see all of them.
Rectal Neoplasms (25) · Colonic Neoplasms (18) · Pancreatic Neoplasms (8) · Stomach Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (4) · Gallbladder Neoplasms (4) · Bile Duct Neoplasms (3) · Breast Neoplasms, Male (3) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Esophageal Neoplasms (3) · Salivary Gland Neoplasms (3) · Appendiceal Neoplasms (2)
Digestive System Diseases (25) · Digestive System Neoplasms (25) · Gastrointestinal Diseases (25) · Intestinal Diseases (25) · Intestinal Neoplasms (25) · Neoplasms by Site (25) · Rectal Diseases (25) · Gastrointestinal Neoplasms (24) · Neoplasms (24) · Colorectal Neoplasms (22) · Colonic Diseases (18) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Pancreatic Diseases (8) · Neoplasms by Histologic Type (6)
Fluorouracil (8) · Oxaliplatin (7) · Bevacizumab (6) · Leucovorin (6) · Capecitabine (3) · Cetuximab (3) · Irinotecan (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2C4 antibody (1) · Control Groups (1) · Dasatinib (1) · Disulfides (1) · Enzyme-Linked Immunosorbent Assay (1) · Erlotinib Hydrochloride (1) · Flow Cytometry (1)
National Cancer Institute (NCI) (15) · City of Hope Medical Center (2) · Anne Noonan (1) · Case Comprehensive Cancer Center (1) · ECOG-ACRIN Cancer Research Group (1) · Istanbul Training and Research Hospital (1) · Mount Sinai Hospital, Canada (1) · Stanford University (1) · University of California, San Francisco (1) · University of Texas Southwestern Medical Center (1)
United States (22) · Canada (2) · Peru (1) · Puerto Rico (1) · Turkey (Türkiye) (1)
Al Benson (1) · Alain Mita (1) · Alessio Pigazzi (1) · Anne M Noonan, MBBChBAO, MSc (1) · Bruce Giantonio (1) · Charles Blanke (1) · Chloe E Atreya, MD, PhD (1) · Christopher Willett (1) · David Ryan (1) · Dean Brenner (1) · James Abbruzzese (1) · Kimmie Ng (1) · Manali Patel (1) · Margaret von Mehren (1) · Marwan Fakih (1)
PMID 24987057, PMID 33142018, PMID 34749008, PMID 35771552
U01CA062490 (2), U10CA021115 (2), N01CM17003 (1), P01CA087971 (1), P30CA014520 (1), P30CA043703 (1), P30CA046592 (1), P30CA054174 (1), R21CA117125 (1), U01CA062491 (1), U01CA069853 (1), U01CA070095 (1), U01CA076576 (1), U01CA099118 (1), U01CA132123 (1)